Dr. Armistead Williams discussed the most recently FDA-approved MS medication, Alemtuzumab, at today’s grand rounds. His discussion of this medication included the following points: Two courses of this potent drug can give people with RRMS 5 years of benefit. The risks include infections and developing a new autoimmune disease, 1 in 3 will get autoimmune thyroid disease and 3% will develop a more serious disease. We have not proven yet that this medication will alter the long term risk of disability or that it is better than an adjustable escalating strategy using medications such as Tysabri, Gilenya or Rituxumab.